Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States)

M. Hisada, B. J V D Berg, Howard Strickler, R. E. Christianson, W. E. Wright, D. J. Waters, C. S. Rabkin

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: Human papilloma virus (HPV) is frequently detectable in cancers of the cervix, vagina, and vulva, but its role in endometrial and ovarian cancers is less certain. This analysis aimed to examine the association of presence of HPV type 16 (HPV-16) antibodies with subsequent risk of cervical, endometrial, and ovarian cancers. Methods: In a prospective study enrolling over 15,000 pregnant women, pre-cancer sera from women who developed cervical (n = 83), endometrial (n = 34), and ovarian (n = 35) cancers were compared with sera from 172 control women frequency-matched by age group and race. Results: HPV-16 seropositivity (OR = 2.0, 95% CI 1.0-3.4) was associated with cervical cancer, with the association more prominent for cancers occurring within 10 years of serum sampling (OR = 2.3, 95% CI 1.0-5.3) than cancers occurring later (OR = 1.6, 95% CI 0.75-3.6). Overall, the associations between HPV-16 seropositivity and endometrial (OR = 1.6, 95% CI 0.64-3.8) and ovarian cancers (OR = 1.1, 95% CI 0.43-2.8) were not significant, although the odds ratios for those cancers occurring within 20 years after serum sampling were similar to that for cervical cancer (OR = 2.2 for both). Conclusions: Our results confirm that HPV-16 infection precedes the development of cervical cancer. Predictability of HPV-16 seropositivity for risk of other female cancers warrants further investigation.

Original languageEnglish (US)
Pages (from-to)335-341
Number of pages7
JournalCancer Causes and Control
Volume12
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Papillomaviridae
Endometrial Neoplasms
Uterine Cervical Neoplasms
Ovarian Neoplasms
Prospective Studies
Antibodies
Neoplasms
Serum
Vaginal Neoplasms
Vulvar Neoplasms
Virus Diseases
Pregnant Women
Research Design
Age Groups
Odds Ratio

Keywords

  • Female cancers
  • HPV-16
  • Serology

ASJC Scopus subject areas

  • Oncology
  • Epidemiology
  • Cancer Research

Cite this

Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States). / Hisada, M.; Berg, B. J V D; Strickler, Howard; Christianson, R. E.; Wright, W. E.; Waters, D. J.; Rabkin, C. S.

In: Cancer Causes and Control, Vol. 12, No. 4, 2001, p. 335-341.

Research output: Contribution to journalArticle

Hisada, M. ; Berg, B. J V D ; Strickler, Howard ; Christianson, R. E. ; Wright, W. E. ; Waters, D. J. ; Rabkin, C. S. / Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States). In: Cancer Causes and Control. 2001 ; Vol. 12, No. 4. pp. 335-341.
@article{c5f5c599a60c42788ebefd30518cdec9,
title = "Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States)",
abstract = "Objective: Human papilloma virus (HPV) is frequently detectable in cancers of the cervix, vagina, and vulva, but its role in endometrial and ovarian cancers is less certain. This analysis aimed to examine the association of presence of HPV type 16 (HPV-16) antibodies with subsequent risk of cervical, endometrial, and ovarian cancers. Methods: In a prospective study enrolling over 15,000 pregnant women, pre-cancer sera from women who developed cervical (n = 83), endometrial (n = 34), and ovarian (n = 35) cancers were compared with sera from 172 control women frequency-matched by age group and race. Results: HPV-16 seropositivity (OR = 2.0, 95{\%} CI 1.0-3.4) was associated with cervical cancer, with the association more prominent for cancers occurring within 10 years of serum sampling (OR = 2.3, 95{\%} CI 1.0-5.3) than cancers occurring later (OR = 1.6, 95{\%} CI 0.75-3.6). Overall, the associations between HPV-16 seropositivity and endometrial (OR = 1.6, 95{\%} CI 0.64-3.8) and ovarian cancers (OR = 1.1, 95{\%} CI 0.43-2.8) were not significant, although the odds ratios for those cancers occurring within 20 years after serum sampling were similar to that for cervical cancer (OR = 2.2 for both). Conclusions: Our results confirm that HPV-16 infection precedes the development of cervical cancer. Predictability of HPV-16 seropositivity for risk of other female cancers warrants further investigation.",
keywords = "Female cancers, HPV-16, Serology",
author = "M. Hisada and Berg, {B. J V D} and Howard Strickler and Christianson, {R. E.} and Wright, {W. E.} and Waters, {D. J.} and Rabkin, {C. S.}",
year = "2001",
doi = "10.1023/A:1011236803257",
language = "English (US)",
volume = "12",
pages = "335--341",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States)

AU - Hisada, M.

AU - Berg, B. J V D

AU - Strickler, Howard

AU - Christianson, R. E.

AU - Wright, W. E.

AU - Waters, D. J.

AU - Rabkin, C. S.

PY - 2001

Y1 - 2001

N2 - Objective: Human papilloma virus (HPV) is frequently detectable in cancers of the cervix, vagina, and vulva, but its role in endometrial and ovarian cancers is less certain. This analysis aimed to examine the association of presence of HPV type 16 (HPV-16) antibodies with subsequent risk of cervical, endometrial, and ovarian cancers. Methods: In a prospective study enrolling over 15,000 pregnant women, pre-cancer sera from women who developed cervical (n = 83), endometrial (n = 34), and ovarian (n = 35) cancers were compared with sera from 172 control women frequency-matched by age group and race. Results: HPV-16 seropositivity (OR = 2.0, 95% CI 1.0-3.4) was associated with cervical cancer, with the association more prominent for cancers occurring within 10 years of serum sampling (OR = 2.3, 95% CI 1.0-5.3) than cancers occurring later (OR = 1.6, 95% CI 0.75-3.6). Overall, the associations between HPV-16 seropositivity and endometrial (OR = 1.6, 95% CI 0.64-3.8) and ovarian cancers (OR = 1.1, 95% CI 0.43-2.8) were not significant, although the odds ratios for those cancers occurring within 20 years after serum sampling were similar to that for cervical cancer (OR = 2.2 for both). Conclusions: Our results confirm that HPV-16 infection precedes the development of cervical cancer. Predictability of HPV-16 seropositivity for risk of other female cancers warrants further investigation.

AB - Objective: Human papilloma virus (HPV) is frequently detectable in cancers of the cervix, vagina, and vulva, but its role in endometrial and ovarian cancers is less certain. This analysis aimed to examine the association of presence of HPV type 16 (HPV-16) antibodies with subsequent risk of cervical, endometrial, and ovarian cancers. Methods: In a prospective study enrolling over 15,000 pregnant women, pre-cancer sera from women who developed cervical (n = 83), endometrial (n = 34), and ovarian (n = 35) cancers were compared with sera from 172 control women frequency-matched by age group and race. Results: HPV-16 seropositivity (OR = 2.0, 95% CI 1.0-3.4) was associated with cervical cancer, with the association more prominent for cancers occurring within 10 years of serum sampling (OR = 2.3, 95% CI 1.0-5.3) than cancers occurring later (OR = 1.6, 95% CI 0.75-3.6). Overall, the associations between HPV-16 seropositivity and endometrial (OR = 1.6, 95% CI 0.64-3.8) and ovarian cancers (OR = 1.1, 95% CI 0.43-2.8) were not significant, although the odds ratios for those cancers occurring within 20 years after serum sampling were similar to that for cervical cancer (OR = 2.2 for both). Conclusions: Our results confirm that HPV-16 infection precedes the development of cervical cancer. Predictability of HPV-16 seropositivity for risk of other female cancers warrants further investigation.

KW - Female cancers

KW - HPV-16

KW - Serology

UR - http://www.scopus.com/inward/record.url?scp=0034968265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034968265&partnerID=8YFLogxK

U2 - 10.1023/A:1011236803257

DO - 10.1023/A:1011236803257

M3 - Article

VL - 12

SP - 335

EP - 341

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 4

ER -